FBIO

1.9007.34%
JJ

J. Jay Lobell

Independent Director

Mr. J. Jay Lobell, J.D., is a co-Founder of Beech Street Capital LLC. Mr. Lobell serves as the President and Chief Operating Officer at Paramount BioCapital Asset Management, Inc. He serves as the President at GMF Capital LLC. He is also the co-founder and Chief Executive Officer of GMF Capital, a commercial real estate and private equity investment firm, since September 2015. Mr. Lobell served as a Consultant at Paramount Capital Investments, LLC. He is a registered Representative of Paramount BioCapital Inc. Mr. Lobell served as President of Meridian Capital Group, LLC from September 2008 to August 2015. Mr. Lobell joined Meridian in 2008. His focus at Meridian, during his seven-year career there, included assisting in charting business strategy for the firm, including the creation and implementation of new business activities. Mr. Lobell served as the President and Chief Operating Officer at Paramount BioSciences, LLC from January 2005 to August 2008. Mr. Lobell currently serves on the Board of Directors of several private companies, including Sava Senior Care, where he has served since September 2013, Tender Touch Rehabilitation Services, where he has served since October 2014 and Pardes Biosciences, where he has served since January 2021 as its Independent Director. Mr. Lobell served as the Chief Executive Officer and Secretary of Chem Rx Corporation since June 1, 2005 and also served as its Chief Financial Officer and Principal Accounting Officer. He served as President and Secretary at Norton Sound Acquisition Corp from August 14, 2005 to August 10, 2007 and its Principal Executive Officer. He has significant experience in financial, regulatory and deal-structuring in health care and biotechnology transactions. He served as the Chief Executive Officer and President at Velcera Inc. from August 2005 to February 27, 2007 and also served as its Secretary. Mr. Lobell served as the Chief Executive Officer, President and Secretary at Denali Sciences, Inc from August 14, 2005 to February 27, 2007. He served as President and Secretary at Sitka Sciences, Inc since August 14, 2005. He was a Partner at Covington & Burling LLP from October 1996 to January 2005, where he advised companies and individuals in a variety of regulatory, transactional and litigation matters. He has been Vice Chairman of Beech Street Capital, LLC since December 2009. Mr. Lobell serves as a Director of Innovive Pharmaceuticals, Inc and Asphelia Pharmaceuticals, Inc. He has been an Independent Director at Fortress Biotech, Inc. (formerly known as Coronado Biosciences, Inc.) since June 2006, Tikvah Therapeutics, Inc since April 2007 and IASO Pharma Inc. since October 2006. Mr. Lobell served as a Director of TRACON Pharmaceuticals, Inc. he served as Director at CytRx Oncology Corporation. He served as Director of Chem Rx Corporation (formerly, Paramount Acquisition Corp.) from June 1, 2005 to January 12, 2010, NovaDel Pharma Inc from December 14, 2005 to October 15, 2009, Norton Sound Acquisition Corp from August 14, 2005 to November 6, 2006 and Sitka Sciences, Inc from August 14, 2005 to November 6, 2006. Mr. Lobell received his B.A., summa cum laude and Phi Beta Kappa from The City University of New York and received his J.D. from Yale Law School in 1988, where he was Senior Editor of the Yale Law Journal.

Positions